ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-LY6G6D/Anti-CD3 T-cell Engager CBI-1214

Its studies are mostly in Colonic Neoplasms, led by Cartography Biosciences.

Furthest: phase 1, since Dec 15, 20251 company-led study, 1 open or runningNext primary completion: Apr 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cartography Biosciences11 open or runningphase 1since Dec 15, 2025Dec 15, 2025Apr 2029phase 1 · NCT07321106

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2025First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT07321106 · 80 planned · United States

Ahead

  1. Apr 2029Primary completion: phase 1 study in Colorectal NeoplasmsNCT07321106

TargetBeta

CD3E →LY6G6D →read by rule
“A bispecific T-cell engager (TCE) directed against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus G6D (LY6G6D) and the T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07321106Colorectal Neoplasms · United States1RecruitingApr 202980

How it is read

Names in the registry

  • “CBI-1214”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.